Human hepatocellular carcinoma HepG2 cells are forced to oxidative phosphorylation (OXPHOS), when cultured in aglycemic conditions at galactose and glutamine. These Oxphos cells represent a prototype of cancer cell bioenergetics with mixed aerobic glycolysis and OXPHOS. We aimed to determine fractions of (i) glutaminolytic pathway involving aminotransferase reaction supplying 2-oxoglutarate (2OG) to the Krebs cycle vs. (ii) active segment of the Krebs cycle with aconitase and isocitrate dehydrogenase-3 (ACO-IDH3), which is typically inactive in cancer cells due to the citrate export from mitochondria. At normoxia, Oxphos cell respiration was decreased down to ~15 and ~10% by the aminotransferase inhibitor aminooxyacetate (AOA) or with AOA plus the glutamate-dehydrogenase inhibitor bithionol, respectively. Phosphorylating to non-phosphorylating respiration ratios dropped from >6.5 to 1.9 with AOA and to zero with AOA plus bithionol. Thus, normoxic Oxphos HepG2 cells rely predominantly on glutaminolysis. Addition of membrane-permeant dimethyl-2-oxoglutarate (dm2OG) to inhibited cells instantly partially restored respiration, evidencing the lack of 2OG-dehydrogenase substrate upon aminotransferase inhibition. Surprisingly, after 72 hr of 5% O2 hypoxia, the AOA (bithionol) inhibition ceased and respiration was completely restored. Thus in aglycemic HepG2 cells, the hypoxia-induced factor (HIF) upregulation of glycolytic enzymes enabled acceleration of glycolysis pathway, preceded by galactolysis (Leloir pathway), redirecting pyruvate via still incompletely blocked pyruvate dehydrogenase toward the ACO-IDH3. Glycolytic flux upregulation at hypoxia was evidently matched by a higher activity of the Leloir pathway in Oxphos cells. Hypoxic Oxphos cells increased 2-fold the NADPH oxidase activity, whereas hypoxic glycolytic cells decreased it. Oxphos cells and glycolytic cells at 5 mM glucose decreased their reduced glutathione fraction. In contrast to aglycemic cells, glycolytic HepG2 cells decreased their respiration at hypoxia despite the dm2OG presence, i.e., even at unlimited respiratory substrate availability for 72 hr at 5% O2, exhibiting the canonical HIF-mediated adaptation. Nevertheless, their ATP content was much higher with dm2OG as compared to its absence during hypoxic adaptation. Thus, the metabolic plasticity of cancer cells is illustrated under conditions frequently established for solid tumors in vivo, such as aglycemia plus hypoxia. Consequently, a wide acceptance of the irreversible and exclusive Warburg phenotype in cancer cells is incorrect.

Department of Mitochondrial Physiology Institute of Physiology Academy of Sciences of the Czech Republic Prague Czechia

Zobrazit více v PubMed

Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer (2016) 16:749 10.1038/nrc.2016.114 PubMed DOI

DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. (2016) 2:e1600200. 10.1126/sciadv.1600200 PubMed DOI PMC

Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene (2016) 35:3619–25. 10.1038/onc.2015.447 PubMed DOI PMC

Smolková K, Plecitá-Hlavatá L, Bellance N, Benard G, Rossignol R, JeŽek P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol. (2011) 43:950–68. 10.1016/j.biocel.2010.05.003 PubMed DOI

Van der Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell (2017) 168:657–69. 10.1016/j.cell.2016.12.039 PubMed DOI PMC

Brocato J, Chervona Y, Costa M. Molecular responses to hypoxia-inducible factor 1α and beyond. Mol Pharmacol. (2014) 85:651–7. 10.1124/mol.113.089623 PubMed DOI PMC

Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J. (2007) 405:1–9. 10.1042/BJ20070389 PubMed DOI

Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell (2012) 148:399–408. 10.1016/j.cell.2012.01.021 PubMed DOI PMC

Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer (2016) 2:758–70. 10.1016/j.trecan.2016.10.016 PubMed DOI

Zepeda AB, Pessoa A, Jr, Castillo RL, Figueroa CA, Pulgar VM, Farías JG. Cellular and molecular mechanisms in the hypoxic tissue: role of HIF-1 and ROS. Cell Biochem Funct. (2013) 31:451–9. 10.1002/cbf.2985 PubMed DOI

Krall AS, Christofk HR. Cancer: a metabolic metamorphosis. Nature (2013) 496:38–40. 10.1038/496038a PubMed DOI

Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. (2006) 3:177–85. 10.1016/j.cmet.2006.02.002 PubMed DOI

Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. (2009) 2:ra73. 10.1126/scisignal.2000431 PubMed DOI PMC

Ouyang Q, Nakayama T, Baytas O, Davidson SM, Yang C, Schmidt M, et al. . Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features. Proc Natl Acad Sci USA. (2016) 113:E5598–607. 10.1073/pnas.1609221113 PubMed DOI PMC

Jadhao SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, et al. . Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology (2004) 39:1297–302. 10.1002/hep.20182 PubMed DOI

Salgado MC, Metón I, Anemaet IG, Baanante IV. Activating transcription factor 4 mediates up-regulation of alanine aminotransferase 2 gene expression under metabolic stress. Biochim Biophys Acta (2014) 1839:288–96. 10.1016/j.bbagrm.2014.01.005 PubMed DOI

Sohocki MM, Sullivan LS, Harrison WR, Sodergren EJ, Elder FF, Weinstock G, et al. . Human glutamate pyruvate transaminase (GPT): localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites. Genomics (1997) 40:247–52. 10.1006/geno.1996.4604 PubMed DOI

Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR, Gong DW. cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics (2002) 79:445–50. 10.1006/geno.2002.6722 PubMed DOI

Yang RZ, Park S, Reagan WJ, Goldstein R, Zhong S, Lawton M, et al. . Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology (2009) 49:598–607. 10.1002/hep.22657 PubMed DOI PMC

Beuster G, Zarse K, Kaleta C, Thierbach R, Kiehntopf M, Steinberg P, et al. . Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth. J Biol Chem. (2011) 286:22323–30. 10.1074/jbc.M110.205229 PubMed DOI PMC

Cao Y, Lin SH, Wang Y, Chin YE, Kang L, Mi J. Glutamic pyruvate transaminase GPT2 promotes tumorigenesis of breast cancer cells by activating sonic hedgehog signaling. Theranostics (2017) 7:3021–33. 10.7150/thno.18992 PubMed DOI PMC

Smolková K, Dvorák A, Zelenka J, Vítek L, JeŽek P. Reductive carboxylation and 2-hydroxyglutarate formation by wild–type IDH2 in breast carcinoma cells. Int J Biochem Cell Biol. (2015) 47:125–33. 10.1016/j.biocel.2015.05.012 PubMed DOI

Yuneva M. Finding an “Achilles' heel” of cancer. Cell Cycle (2008) 7:2083–9. 10.4161/cc.7.14.6256 PubMed DOI

Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC dependent apoptosis in human cells. J Cell Biol. (2007) 178:93–105. 10.1083/jcb.200703099 PubMed DOI PMC

Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. . Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. (2008) 105:18782–7. 10.1073/pnas.0810199105 PubMed DOI PMC

Petrovic S, Krajnović-Ozretić M, Ozretić B. Isolation and properties of mitochondrial aspartate aminotransferase from red muscle of grey mullet, Mugil auratus Risso. Biochim Biophys Acta (1994) 1207:201–7. PubMed

Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol. (2012) 18:3775–81. 10.3748/wjg.v18.i29.3775 PubMed DOI PMC

Hull J, Hindy ME, Kehoe PG, Chalmers K, Love S, Conway ME. Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. J Neurochem. (2012) 123:997–1009. 10.1111/jnc.12044 PubMed DOI

Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z, et al. . Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. (2014) 7:1679–90. 10.1016/j.celrep.2014.04.037 PubMed DOI PMC

Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. (2018) 12:9–26. 10.2174/2213988501812010009 PubMed DOI PMC

McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. (2014) 87:20130676. 10.1259/bjr.20130676 PubMed DOI PMC

Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget (2017) 8:46691–703. 10.18632/oncotarget.17358 PubMed DOI PMC

Xiong XX, Qiu XY, Hu DX, Chen XQ. Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma. Mol Pharmacol. (2017) 92:246–55. 10.1124/mol.116.107706 PubMed DOI

Lévy PL, Duponchel S, Eischeid H, Molle J, Michelet M, Diserens G, et al. . Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology (2017) 65:789–803. 10.1002/hep.28949 PubMed DOI

Xu P, Oosterveer MH, Stein S, Demagny H, Ryu D, Moullan N, et al. . LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer. Genes Dev. (2016) 30:1255–60. 10.1101/gad.277483.116 PubMed DOI PMC

Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. (2004) 64:985–93 10.1158/0008-5472.CAN-03-1101 PubMed DOI

Plecitá-Hlavatá L, JeŽek J, JeŽek P. Aglycemia keeps mitochondrial oxidative phosphorylation under hypoxic conditions in HepG2 cells. J Bioenerg Biomembr. (2015) 47:467–76. 10.1007/s10863-015-9628-6 PubMed DOI

Plecitá-Hlavatá L, Engstová H, Alán L, Špaček T, Dlasková A, Smolková K, et al. . Hypoxic HepG2 cell adaptation decreases ATP synthase dimers and ATP production in inflated cristae by mitofilin down-regulation concomitant to MICOS clustering. FASEB J. (2016) 30:1941–57. 10.1096/fj.201500176 PubMed DOI

Morava E. Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol Genet Metab. (2014) 112:275–9. 10.1016/j.ymgme.2014.06.002 PubMed DOI PMC

Tang M, Etokidem E, Lai K. The leloir pathway of galactose metabolism - a novel therapeutic target for hepatocellular carcinoma. Anticancer Res. (2016) 36:6265–71. 10.21873/anticanres.11221 PubMed DOI

Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism. Int J Cell Biol. (2012) 2012:282041. 10.1155/2012/282041 PubMed DOI PMC

Björnson E, Mukhopadhyay B, Asplund A, Pristovsek N, Cinar R, Romeo S, et al. . Stratification of hepatocellular carcinoma patients based on acetate utilization. Cell Rep (2015) 13:2014–26. 10.1016/j.celrep.2015.10.045 PubMed DOI

Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. (2017) 401:39–45. 10.1016/j.canlet.2017.05.002 PubMed DOI

Goetzman ES, Prochownik EV. The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front Endocrinol. (2018) 9:129. 10.3389/fendo.2018.00129 PubMed DOI PMC

Amiri M, Yousefnia S, Forootan FS, Peymani M, Ghaedi K, Esfahani MHN. Diverse roles of fatty acid binding proteins (FABPs) in development and pathogenesis of cancers. Gene (2018) 676:171–83. 10.1016/j.gene.2018.07.035 PubMed DOI

Melone MAB, Valentino A, Margarucci S, Galderisi U, Giordano A, Peluso G. The carnitine system and cancer metabolic plasticity. Cell Death Dis. (2018) 9:228. 10.1038/s41419-018-0313-7 PubMed DOI PMC

Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. . Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 461:109–13. 10.1038/nature08268 PubMed DOI PMC

Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. . Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. (2011) 25:1041–51. 10.1101/gad.1987211 PubMed DOI PMC

Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature (2012) 485:661–5. 10.1038/nature11066 PubMed DOI PMC

Aiderus A, Black MA, Dunbier AK. Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. BMC Cancer (2018) 18:805. 10.1186/s12885-018-4626-9 PubMed DOI PMC

JeŽek J, Engstová H, JeŽek P. Antioxidant mechanism of mitochondria-targeted plastoquinone SkQ1 is suppressed in aglycemic HepG2 cells dependent on oxidative phosphorylation. Biochim Biophys Acta Bioenerg. (2017) 858:750–62. 10.1016/j.bbabio.2017.05.005 PubMed DOI

MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, et al. . Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol. (2007) 27:3282–9. 10.1128/MCB.01927-06 PubMed DOI PMC

Li M, Smith CJ, Walker MT, Smith TJ. Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. (2009) 284:22988–3000. 10.1074/jbc.M109.020222 PubMed DOI PMC

JeŽek P, Plecitá-Hlavatá L, Smolková K, Rossignol R. Distinctions and similarities of cell bioenergetics and role of mitochondria in hypoxia, cancer, and embryonic development. Int J Biochem Cell Biol. (2010) 42:604–22. 10.1016/j.biocel.2009.11.008 PubMed DOI

Vaupel P, Mayer A. Tumor oxygenation status: facts and fallacies. Adv Exp Med Biol. (2017) 977:91–9. 10.1007/978-3-319-55231-6_13 PubMed DOI

Smolková K, Bellance N, Scandurra F, Génot E, Gnaiger E, Plecitá-Hlavatá L, et al. . Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia. J Bioenerg Biomembr. (2010) 42:55–67. 10.1007/s10863-009-9267-x PubMed DOI

Dott W, Mistry P, Wright J, Cain K, Herbert KE. Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity. Redox Biol. (2014) 2:224–33. 10.1016/j.redox.2013.12.028 PubMed DOI PMC

Sauer LA, Dauchy RT, Nagel WO, Morris HP. Mitochondrial malic enzymes. Mitochondrial NAD(P)+-dependent malic enzyme activity and malate-dependent pyruvate formation are progression-linked in Morris hepatomas. J Biol Chem. (1980) 255:3844–8. PubMed

Mitochondrial Physiology of Cellular Redox Regulations

Mitochondrial Cristae Morphology Reflecting Metabolism, Superoxide Formation, Redox Homeostasis, and Pathology

Potential of Mitochondria-Targeted Antioxidants to Prevent Oxidative Stress in Pancreatic β-cells